ClinicalTrials.gg
RecruitingNCT06346093Updated Jun 10, 2025

Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer

An interventional study of Fecal Microbiota Transplantation Capsules and Placebo in Advanced Gastric Cancer, sponsored by Changhai Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Stomach Neoplasms by Changhai Hospital — 4 open to participants now, 4 under way, none of them phase 3. Stomach Neoplasms · Changhai Hospital.

Started
2024
with 1 other
No phase
5 of 10
2 open now
Registered
6th of 10
by date

Among the 10 studies in Stomach Neoplasms by Changhai Hospital, this one is one of 2 that started in 2024, is one of 5 with no phase, and was the 6th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

4 of the 10 studies in Stomach Neoplasms by Changhai Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Stomach Neoplasms by Changhai Hospital, or all of them as a file.
02

Study summary

This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD1/PDL1 therapy in the advanced gastric cancer.

03

Conditions studied

  • Advanced Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Voluntarily participate in this study and provide written . Age ≥ 18 years , male or female. Pathological confirmed locally advanced, unresectable or gastric adenocarcinoma, esophagogastric junction adenocarcinoma.

Able and willing to provide tumor tissue. At least one measurable extracranial target lesion according to . (ECOG) Performance Status of 0 or 1. ≥3 months.

Exclusion criteria

Exclusion Criteria:

Presence of absolute to FMT administration:Toxic megacolon;Inflammatory bowel disease;Anatomic contra-indications to colonoscopy;Colectomy Patient is currently participating and receiving other study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 4 weeks of this study intervention.

Currently under any form of systemic antibiotics. Has a diagnosis of immunodeficiency or is receiving systemic therapy (> 10 mg prednisone daily or equivalent) or any other form of therapy two weeks prior to trial treatment. Patients receiving systemic steroids at physiologic doses are permitted to enroll assuming steroid dose is not above the acceptable threshold (> 10 mg prednisone daily or equivalent).

Severe anaphylactic reaction to any food (food allergies). Had a severe reaction to propofol. Has serious concomitant illnesses. The eligibility can be granted by the treating investigator on individual bases.

Has infection or AIDS-related illness. Has active infection of HAV, or . Patients with a history of Hepatitis B/C infection who have received anti-viral therapy and are disease free may be considered for enrollment after discussion with Principal Investigator.

Patient has received a within 4 weeks prior to the first dose of treatment. Seasonal influenza vaccines or COVID-19 vaccines for injection are generally inactivated virus vaccines and are allowed.

Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Females who are pregnant or breastfeeding. Active central nervous system (CNS) and/or

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
124 participants (estimated)

Study arms

  • Placebo comparator
    Placebo capsules

    Placebo capsules will be administered orally three days and then every three weeks for 24 weeks. SOX and anti-PD1/PD-L1 will be intravenously infused every three weeks for 24 weeks.

    Procedure: Placebo

  • Experimental
    FMT capsules

    FMT capsules will be administered orally three days and then every three weeks for 24 weeks. SOX and anti-PD1/PD-L1 will be intravenously infused every three weeks for 24 weeks.

    Procedure: Fecal Microbiota Transplantation Capsules

Interventions

  • ProcedureFecal Microbiota Transplantation Capsules

    FMT Capsules in Combination with Chemotherapy and Anti-PD1/PD-L1 Therapy

    Also known as: FMT Capsules

  • ProcedurePlacebo

    Mainly composed of starch, the appearance, shape, color, and size are exactly the same as FMT capsules

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the percentage of subjects who had a complete response (CR) or partial response (PR), as defined by ir-RECIST v1.1, and is based on the best response obtained.

    Time frame: up to 6 months

  2. Rate of Disease Control

    Rate of Disease Control is defined as the percentage of subjects who had a complete response (CR), partial response (PR), or stable disease (SD), as defined by ir-RECIST v1.1.

    Time frame: up to 6 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    The median length of time from initiation of study drug(s) disease progression as defined by RECIST v1.1, or death. Progressive Disease (PD): ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: up to 2 years

  2. Overall Survival (OS)

    The length of time (in days) from study intervention that participants remain alive.

    Time frame: up to 2 years

  3. Incidence of Adverse Events Related to Treatment

    All adverse events and their relationships to study drugs and procedures will be recorded,to assess overall safety, feasibility and tolerability of treatment.

    Time frame: up to 6 months

  4. Change in the intestinal microbiome community

    Mean change from baseline of bacterial species compared with 6 months post fecal microbiota transplantation (FMT).

    Time frame: up to 6 months

  5. Quality of life based on the questionnaire

    The EORTC QLQ-STO22/EORTC QLQ-C30 questionnaire will be used to assess the quality of life of the participants.

    Time frame: up to 2 years

  6. Change in the immunity

    Mean change from baseline of immune cells compared with 6 months post fecal microbiota transplantation (FMT).

    Time frame: up to 6 months

Other outcomes

  1. Marker of nutritional status

    Hemoglobin is a measure of the nutritional status and are seen as markers for the catabolic state of cachectic cancer patients.

    Time frame: up to 2 years

  2. Marker of nutritional status

    Creatinin is a measure of the nutritional status and is seen as markers for the catabolic state of cachectic cancer patients.

    Time frame: up to 2 years

  3. Marker of nutritional status

    Albumin is a measure of the nutritional status and is seen as markers for the catabolic state of cachectic cancer patients.

    Time frame: up to 2 years

  4. Body Weight

    Body Weight Change. (kilograms)

    Time frame: up to 2 years

  5. Appetite

    Appetite measured by FAACT

    Time frame: up to 2 years

  6. Marker of nutritional status

    C-reactief proteïne is a measure of the nutritional status and is seen as markers for the catabolic state of cachectic cancer patients.

    Time frame: up to 2 years

  7. Marker of nutritional status

    Lactate dehydrogenase (LDH) is a measure of the nutritional status and is seen as markers for the catabolic state of cachectic cancer patients.

    Time frame: up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jun 2030, 74 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 74 months is above that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Apr 3, 2024
StartActual
Apr 2, 2024
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06346093
Lead sponsor
Changhai Hospital
Responsible party
Xiangyu Kong (Principle Investigator, Changhai Hospital) — Principal investigator
First posted
Apr 3, 2024
Start date
Apr 2, 2024
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Jun 10, 2025

Study contacts

Xiangyu Kong, associate professor
Contact
xiangyukong185@hotmail.com
13564644397

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion